- Home
- KRON vs ECOR Comparison
KRON vs ECOR Comparison
Compare KRON & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- ECOR
- Stock Information
- Founded
- KRON 2017
- ECOR 2005
- Country
- KRON United States
- ECOR United States
- Employees
- KRON 8
- ECOR N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- KRON Health Care
- ECOR Health Care
- Exchange
- KRON Nasdaq
- ECOR Nasdaq
- Market Cap
- KRON 54.1M
- ECOR 50.1M
- IPO Year
- KRON 2020
- ECOR 2018
- Fundamental
- Price
- KRON $0.88
- ECOR $5.21
- Analyst Decision
- KRON Buy
- ECOR Strong Buy
- Analyst Count
- KRON 3
- ECOR 2
- Target Price
- KRON $1.63
- ECOR $25.50
- AVG Volume (30 Days)
- KRON 1.4M
- ECOR 70.6K
- Earning Date
- KRON 08-07-2025
- ECOR 08-06-2025
- Dividend Yield
- KRON N/A
- ECOR N/A
- EPS Growth
- KRON N/A
- ECOR N/A
- EPS
- KRON N/A
- ECOR N/A
- Revenue
- KRON $9,192,000.00
- ECOR $26,458,000.00
- Revenue This Year
- KRON N/A
- ECOR $23.21
- Revenue Next Year
- KRON N/A
- ECOR $44.10
- P/E Ratio
- KRON N/A
- ECOR N/A
- Revenue Growth
- KRON 21.16
- ECOR 41.54
- 52 Week Low
- KRON $0.65
- ECOR $4.47
- 52 Week High
- KRON $1.60
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- KRON 65.76
- ECOR 45.80
- Support Level
- KRON $0.87
- ECOR $5.13
- Resistance Level
- KRON $0.90
- ECOR $5.69
- Average True Range (ATR)
- KRON 0.01
- ECOR 0.37
- MACD
- KRON -0.00
- ECOR 0.03
- Stochastic Oscillator
- KRON 40.19
- ECOR 26.04
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.